Both (DMFS and MSS) were significantly shorter in patients with primary melanomas showing IGF2BP3 mRNA expression levels above the median (median MSS: 60.81% vs. 89.88%, p = 0.015 and median DMFS: 47.79% vs. 89.33%, p < 0.001, respectively) (Figure 4a,b). This evidence concerns the gene IGF2BP3 and melanoma.